Risk of fetal loss associated with invasive testing following combined first‐trimester screening for Down syndrome: a national cohort of 147 987 singleton pregnancies

To assess prospectively the risk of fetal loss associated with chorionic villus sampling (CVS) and amniocentesis (AC) following combined first‐trimester screening (cFTS) for Down syndrome.

[1]  L. Hui,et al.  Population‐based trends in prenatal screening and diagnosis for aneuploidy: a retrospective analysis of 38 years of state‐wide data , 2016, BJOG : an international journal of obstetrics and gynaecology.

[2]  Etty Daniel-Spiegel,et al.  [TURNING THE PYRAMID IN PRENATAL CARE]. , 2015, Harefuah.

[3]  N. Uldbjerg,et al.  The Danish Fetal Medicine Database: establishment, organization and quality assessment of the first trimester screening program for trisomy 21 in Denmark 2008–2012 , 2015, Acta obstetricia et gynecologica Scandinavica.

[4]  F. D’Antonio,et al.  Procedure‐related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta‐analysis , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[5]  P. Austin.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies , 2011, Multivariate behavioral research.

[6]  K. Nicolaides,et al.  Prediction of miscarriage and stillbirth at 11–13 weeks and the contribution of chorionic villus sampling , 2011, Prenatal diagnosis.

[7]  Z. Alfirevic,et al.  Update on Procedure-Related Risks for Prenatal Diagnosis Techniques , 2009, Fetal Diagnosis and Therapy.

[8]  A. Tabor,et al.  Fetal loss rate after chorionic villus sampling and amniocentesis: an 11‐year national registry study , 2009, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[9]  A. Tabor,et al.  Impact of a new national screening policy for Down’s syndrome in Denmark: population based cohort study , 2008, BMJ : British Medical Journal.

[10]  F. Malone,et al.  Prediction of patient-specific risk for fetal loss using maternal characteristics and first- and second-trimester maternal serum Down syndrome markers. , 2008, American journal of obstetrics and gynecology.

[11]  Z. Alfirevic,et al.  Procedure-Related Complications of Amniocentesis and Chorionic Villous Sampling: A Systematic Review , 2007, Obstetrics and gynecology.

[12]  H. V. Houwelingen.  Dynamic Prediction by Landmarking in Event History Analysis , 2007 .

[13]  K. Nicolaides,et al.  First‐trimester ultrasound and biochemical markers of aneuploidy and the prediction of impending fetal death , 2006, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[14]  J. Lunceford,et al.  Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study , 2004, Statistics in medicine.

[15]  A. Andersen,et al.  Maternal age and fetal loss: population based register linkage study , 2000, BMJ : British Medical Journal.

[16]  S. Cicero,et al.  Screening for triploidy by fetal nuchal translucency and maternal serum free β‐hCG and PAPP‐A at 10–14 weeks of gestation , 2000, Prenatal diagnosis.

[17]  Y. T. van der Schouw,et al.  Learning in medicine: chorionic villus sampling , 2000, Prenatal diagnosis.

[18]  K. Spencer,et al.  Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β ‐hCG and PAPP‐A at 10–14 weeks of gestation , 1999, Prenatal diagnosis.

[19]  K. Nicolaides,et al.  A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translucency, maternal serum free β‐human chorionic gonadotropin and pregnancy‐associated plasma protein‐A , 1999, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[20]  G. Szemere,et al.  First‐trimester ultrasound screening for fetal aneuploidies in women over 35 and under 35 years of age , 1995, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[21]  K. Nicolaides,et al.  Comparison of chorionic villus sampling and amniocentesis for fetal karyotyping at 10-13 weeks' gestation , 1994, The Lancet.

[22]  J. Carlin,et al.  Importance of complete follow-up of spontaneous fetal loss after amniocentesis and chorion villus sampling , 1992, The Lancet.

[23]  K. Nicolaides,et al.  Fetal nuchal translucency: ultrasound screening for chromosomal defects in first trimester of pregnancy. , 1992, BMJ.

[24]  T. Hastie,et al.  Generalized Additive Models , 2014 .

[25]  Ann Tabor,et al.  RANDOMISED CONTROLLED TRIAL OF GENETIC AMNIOCENTESIS IN 4606 LOW-RISK WOMEN , 1986, The Lancet.

[26]  J M Robins,et al.  Estimation of a common effect parameter from sparse follow-up data. , 1985, Biometrics.

[27]  D. Rubin,et al.  The central role of the propensity score in observational studies for causal effects , 1983 .

[28]  J. Fleming,et al.  A CRITICAL EVALUATION OF SONAR “CROWN‐RUMP LENGTH” MEASUREMENTS , 1975, British journal of obstetrics and gynaecology.

[29]  E. Gerdts.  Letter: Cervical cancer and gonorrhoea. , 1974, Lancet.